GlassScriptPhysician profile
Peter B Lindy
NPI 1558323501
$3,215.62
in general payments reported to CMS, 2019-2025
23 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $150 · 2021: $72.42 · 2022: $1,341 · 2023: $589 · 2024: $420 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552 · Travel and Lodging: $468 · Consulting Fee: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.53 |
| Travel and Lodging | $468.16 |
| Consulting Fee | $240.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gentleman Orthopedic Solutions | $1,200.00 | 2022 | |
| Arthrex, INC. | $589.16 | 2023 | |
| Conformis, INC. | $289.97 | 2019-2022 | |
| Becton, Dickinson and Company | $240.00 | 2024 | |
| Restor3d, INC. | $160.21 | 2025 | |
| Smith+Nephew, INC. | $140.00 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $121.83 | 2024 | Exparel |
| Ferring Pharmaceuticals INC. | $74.28 | 2019-2022 | |
| Bioventus LLC | $53.55 | 2021-2024 | Exogen Ultrasound Bone Healing System |
| Heron Therapeutics, INC. | $47.14 | 2021-2024 | Zynrelef |
| Innovation Technologies INC | $41.88 | 2025 | Irrisept |
| Convatec INC. | $39.41 | 2022-2025 | |
| Medtronic USA, INC. | $34.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.55 | 2019 | |
| Solventum Corporation | $27.39 | 2025 | V.A.C.Ulta, Activ.A.C. |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $23.76 | 2020 | |
| Osiris Therapeutics INC. | $18.13 | 2019 | |
| Davol INC. | $16.93 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.63 | 2022 | |
| Amgen INC. | $15.08 | 2022 | |
| Kci USA, INC. | $13.44 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.37 | 2019 | |
| Allergan, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lindy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.